Article

PIKfyve controls dendritic cell function and tumor immunity

2024-03-02

Abstract excerpt

The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and affect immunotherapy are poorly understood. Here, we report that among shared gene targets of clinically relevant protein kinase inhibitors, high PIKFYVE expression was least predict...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b3c042a5-1aa8-593c-8c9c-17e61e486b60
DOI: 10.1101/2024.02.28.582543

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PIKfyve controls dendritic cell function and tumor immunityDOI 10.1101/2024.02.28.582543Read

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapySemantic proximity Read

The non-linearity of RAF-MEK signaling in dendritic cells.Semantic proximity Read

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read

FSCN1 Modulates Tumor Growth and Innate Immune Pathways through Synergistic Interaction with PIK3CA MutationsSemantic proximity Read

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.Semantic proximity Read

Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapySemantic proximity Read

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwaySemantic proximity Read

Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activationSemantic proximity Read

FIP200 Suppresses Immune Checkpoint Therapy Responses in Breast Cancers by Limiting AZI2/TBK1/IRF Signaling Independent of Its Canonical Autophagy FunctionSemantic proximity Read

PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor SignalingSemantic proximity Read

Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell ImmunitySemantic proximity Read

Selective targeting of Mnk2 Drives Proteomic Rewiring of Tumor-Associated Macrophages to Restore Antitumor Immunity and suppress tumor progressionSemantic proximity Read